Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Amortization of Deferred Charges for 4 consecutive years, with -$465000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 173.93% to -$465000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 37.5% increase, with the full-year FY2025 number at $3.0 million, up 37.5% from a year prior.
  • Amortization of Deferred Charges was -$465000.0 for Q4 2025 at Phathom Pharmaceuticals, down from $1.2 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $1.9 million in Q3 2023 to a low of -$484000.0 in Q4 2022.
  • A 4-year average of $681187.5 and a median of $580000.0 in 2022 define the central range for Amortization of Deferred Charges.
  • Biggest YoY gain for Amortization of Deferred Charges was 918.75% in 2025; the steepest drop was 173.93% in 2025.
  • Phathom Pharmaceuticals' Amortization of Deferred Charges stood at -$484000.0 in 2022, then skyrocketed by 285.74% to $899000.0 in 2023, then plummeted by 30.03% to $629000.0 in 2024, then plummeted by 173.93% to -$465000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Amortization of Deferred Charges are -$465000.0 (Q4 2025), $1.2 million (Q3 2025), and $1.6 million (Q2 2025).